Health Care & Life Sciences » Pharmaceuticals | Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc. | Cash Flow

Fiscal year is December-November. All values CAD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
11,776.50
4,230.30
9,375.30
13,471.90
11,537.30
Depreciation, Depletion & Amortization
406.50
418.40
476.40
511.60
678.40
Other Funds
5,783.10
2,083.90
639.10
3,181.20
2,945.20
Funds from Operations
5,586.90
1,728.00
8,259.80
9,779.10
7,913.70
Changes in Working Capital
1,509.60
153.20
3,491.50
1,471.80
39.40
Net Operating Cash Flow
7,096.40
1,881.20
4,768.30
8,307.40
7,953.10
Capital Expenditures
125.00
843.50
542.70
684.50
2,375.50
Net Investing Cash Flow
125.00
843.50
542.70
684.50
2,375.50
Issuance/Reduction of Debt, Net
1,485.50
869.60
34.70
28.30
214.70
Net Financing Cash Flow
7,507.90
6,534.90
2,185.90
12,165.10
7,401.30
Net Change in Cash
270.00
3,810.20
3,125.10
3,173.20
2,927.30
Free Cash Flow
7,221.40
2,724.70
5,311.00
8,991.90
10,328.70
Change in Capital Stock
6,022.40
7,404.50
2,220.60
12,193.40
7,616.00
Exchange Rate Effect
16.40
-
-
-
-

About Intellipharmaceutics International

View Profile
Address
30 Worcester Road
Toronto Ontario M9W 5X2
Canada
Employees -
Website http://www.intellipharmaceutics.com
Updated 09/14/2018
Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of existing and new pharmaceuticals in the areas of neurology, cardiovascular, gastrointestinal tract, diabetes and pain. The company was founded by Isa Odidi and Amina Odidi on October 22, 2009 and is headquartered in Toronto, Canada.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.